Evolocumab 140 MG/ML [Repatha]

DRUG3 trials

Sponsors

Radboud University Medical Center, University Hospital, Grenoble, General Hospital of Shenyang Military Region

Conditions

Atherosclerosis of Coronary ArteryAtherosclerotic Cardiovascular DiseaseCoronary Artery DiseaseHypertriglyceridemia Induced Acute Pancreatitis

Phase 2

Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography

University Hospital, GrenobleAtherosclerotic Cardiovascular Disease

Start: 2021-01-08End: 2022-11-30Target: 66Updated: 2022-05-19

Unknown Phase

Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody

CompletedNCT04141579

Radboud University Medical CenterAtherosclerosis of Coronary Artery, Coronary Artery Disease

Start: 2020-11-10End: 2023-11-09Updated: 2024-07-18

Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis

RecruitingNCT07388420

General Hospital of Shenyang Military RegionHypertriglyceridemia Induced Acute Pancreatitis

Start: 2026-01-02End: 2026-12-31Target: 40Updated: 2026-02-05

Related Papers

Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial.

2026-03-23

Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial

EuroIntervention2025-08-014 citations

Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial.

2024-09-181 citations

Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study)

BMJ Open2024-07-014 citations